(Q36162359)

12 August 2017

1 reference

title

Therapy of hepatitis C in patients with HIV infection (English)

1 reference

12 August 2017

Tami Daugherty

1

1 reference

12 August 2017

Maurizio Bonacini

series ordinal

2

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

375-384

1 reference

Hepatitis C and HIV-1 coinfection

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Care of patients with hepatitis C and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.375

21 January 2018

Identifiers

DOI

10.1586/14787210.3.3.375

1 reference

12 August 2017

1 reference